VALIDATION IMAGES
IF(ICC) staining with Caveolin-1 (9C11) Monoclonal Antibody (bsm-52303R) at 1:100 in A549 cells (green). The nuclear counterstain is DAPI (blue). Cells were fixed in paraformaldehyde, permeabilized with 0.25% Triton X100/PBS.
IF(ICC) staining with Caveolin-1 (9C11) Monoclonal Antibody (bsm-52303R) at 1:100 in MCF-7 cells (green). The nuclear counterstain is DAPI (blue). Cells were fixed in paraformaldehyde, permeabilized with 0.25% Triton X100/PBS.
IF(ICC) staining with Caveolin-1 (9C11) Monoclonal Antibody (bsm-52303R) at 1:100 in NIH/3T3 cells (green). The nuclear counterstain is DAPI (blue). Cells were fixed in paraformaldehyde, permeabilized with 0.25% Triton X100/PBS.
Paraformaldehyde-fixed and paraffin-embedded Mouse liver tissue incubated with Caveolin-1 (9C11) Monoclonal Antibody (bsm-52303R) at 1:100, overnight at 4°C, followed by a conjugated secondary antibody and DAB staining. Counterstained with hematoxylin.
Paraformaldehyde-fixed and paraffin-embedded Human lung tissue incubated with Caveolin-1 (9C11) Monoclonal Antibody (bsm-52303R) at 1:100, overnight at 4°C, followed by a conjugated secondary antibody and DAB staining. Counterstained with hematoxylin.
Paraformaldehyde-fixed and paraffin-embedded Mouse heart tissue incubated with Caveolin-1 (9C11) Monoclonal Antibody (bsm-52303R) at 1:100, overnight at 4°C, followed by a conjugated secondary antibody and DAB staining. Counterstained with hematoxylin.
Paraformaldehyde-fixed and paraffin-embedded Human liver tissue incubated with Caveolin-1 (9C11) Monoclonal Antibody (bsm-52303R) at 1:100, overnight at 4°C, followed by a conjugated secondary antibody and DAB staining. Counterstained with hematoxylin.
Paraformaldehyde-fixed and paraffin-embedded Mouse lung tissue incubated with Caveolin-1 (9C11) Monoclonal Antibody (bsm-52303R) at 1:100, overnight at 4°C, followed by a conjugated secondary antibody and DAB staining. Counterstained with hematoxylin.
Lane 1: A549 Cells; Probed with Caveolin-1 (9C11) Monoclonal Antibody (bsm-52303R) at 1:1000, overnight at 4°C followed by a conjugated secondary antibody for 60 minutes at 37°C.